#,ama,title,journal,year,volume,issue,pages,doi,pmid,authors
1,"R. Government Health and Social Care Directorate of the Chief Scientist Office. Littleford reports grants from the Scottish Government Health and Social Care Directorate of the Chief Scientist Office and Oncimmune, during the conduct of the study. None;None.",Government Health and Social Care Directorate of the Chief Scientist Office,"Littleford reports grants from the Scottish Government Health and Social Care Directorate of the Chief Scientist Office and Oncimmune, during the conduct of the study",,,,,,,R
2,"Mccowan C. N. McMeekin reports grants from Oncimmune and the Scottish Government Health and Social Care Directorate of the Chief Scientist Office, during the conduct of the study. N. McMeekin reports grants from Oncimmune and the Scottish Government Health and Social Care Directorate of the Chief Scientist Office, during the conduct of the study. None;None.","N. McMeekin reports grants from Oncimmune and the Scottish Government Health and Social Care Directorate of the Chief Scientist Office, during the conduct of the study","N. McMeekin reports grants from Oncimmune and the Scottish Government Health and Social Care Directorate of the Chief Scientist Office, during the conduct of the study",,,,,,,Mccowan C
3,Robertson C. reports personal fees and other funding from Oncimmune. reports personal fees and other funding from Oncimmune. None;None.,reports personal fees and other funding from Oncimmune,reports personal fees and other funding from Oncimmune,,,,,,,Robertson C
4,Robles J. Zurita reports grants from the Scottish Government Health and Social Care Directorate of the Chief. Zurita reports grants from the Scottish Government Health and Social Care Directorate of the Chief. None;None. doi:10.1183/13993003.00670-2020References.,Zurita reports grants from the Scottish Government Health and Social Care Directorate of the Chief,Zurita reports grants from the Scottish Government Health and Social Care Directorate of the Chief,,,,,10.1183/13993003.00670-2020References,,Robles J
5,"Allemani C, Matsuda T, Carlo D, V. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391.",Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries,Lancet,2018,391,,,,,Allemani C; Matsuda T; Carlo D; V
6,"National T, Screening L, Research T, T. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365.",Reduced lung-cancer mortality with low-dose computed tomographic screening,N Engl J Med,2011,365,,,,,National T; Screening L; Research T; T
7,"National T, Screening L, Research T, T. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019;14.",Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial,J Thorac Oncol,2019,14,,,,,National T; Screening L; Research T; T
8,"De Koning HJ, Van Der Aalst CM, Jong PA. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382.",Reduced lung-cancer mortality with volume CT screening in a randomized trial,N Engl J Med,2020,382,,,,,De Koning HJ; Van Der Aalst CM; Jong PA
9,"Infante M, Cavuto S, Lutman F. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Ann Oncol. 2019;30.","Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography",Ann Oncol,2019,30,,,,,Infante M; Cavuto S; Lutman F
10,"Pastorino U, Silva M, Sestini S. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial. Ann Oncol. 2019;30.",Prolonged lung cancer screening reduced 10-year mortality in the MILD trial,Ann Oncol,2019,30,,,,,Pastorino U; Silva M; Sestini S
11,"Huang KL, Wang SY, Lu WC. Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysis. BMC Pulm Med. 2019;19:126.","Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysis",BMC Pulm Med,2019,19,,126,,,Huang KL; Wang SY; Lu WC
12,"Becker N, Motsch E, Trotter A. Lung cancer mortality reduction by LDCT screeningresults from the randomized German LUSI trial. Int J Cancer. 2019;1513.",Lung cancer mortality reduction by LDCT screeningresults from the randomized German LUSI trial,Int J Cancer,2019,1513,,,,,Becker N; Motsch E; Trotter A
13,"Wille M, Dirksen A, Ashraf H. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193.",Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling,Am J Respir Crit Care Med,2016,193,,,,,Wille M; Dirksen A; Ashraf H
14,"Han D, Heuvelmans MA, Vliegenthart R. An update on the European lung cancer screening trials and comparison of lung cancer screening recommendations in Europe. J Thorac Imaging. 2019;34.",An update on the European lung cancer screening trials and comparison of lung cancer screening recommendations in Europe,J Thorac Imaging,2019,34,,,,,Han D; Heuvelmans MA; Vliegenthart R
15,"Oudkerk M, Devaraj A, Vliegenthart R. European position statement on lung cancer screening. Lancet Oncol. 2017;18.",European position statement on lung cancer screening,Lancet Oncol,2017,18,,,,,Oudkerk M; Devaraj A; Vliegenthart R
16,"Li Y, Karjalainen A, Koskinen H. p53 autoantibodies predict subsequent development of cancer. Int J Cancer. 2005;114.",p53 autoantibodies predict subsequent development of cancer,Int J Cancer,2005,114,,,,,Li Y; Karjalainen A; Koskinen H
17,"Robertson J, Chapman C, Cheung K. Autoantibodies in early breast cancer. J Clin Oncol. 2005;23.",Autoantibodies in early breast cancer,J Clin Oncol,2005,23,,,,,Robertson J; Chapman C; Cheung K
18,"Chapman CJ, Healey GF, Murray A. EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol. 2012;33.",EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays,Tumor Biol,2012,33,,,,,Chapman CJ; Healey GF; Murray A
19,"Jett JR, Peek LJ, Fredericks L. Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014;83.","Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice",Lung Cancer,2014,83,,,,,Jett JR; Peek LJ; Fredericks L
20,"Sullivan FM, Farmer E, Mair FS. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer. 2017;17:187.",Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT-Lung Test (ECLS): study protocol for a randomized controlled trial,BMC Cancer,2017,17,,187,,,Sullivan FM; Farmer E; Mair FS
21,"Weller D, Vedsted P, Rubin G. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer. 2012;106.",The Aarhus statement: improving design and reporting of studies on early cancer diagnosis,Br J Cancer,2012,106,,,,,Weller D; Vedsted P; Rubin G
22,"Schulz KF, Altman DG, Moher D. 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:332.",2010 statement: updated guidelines for reporting parallel group randomised trials,BMJ,2010,340,,332,,,Schulz KF; Altman DG; Moher D
23,"Macmahon H, Naidich DP, Goo JM. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284.",Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017,Radiology,2017,284,,,,,Macmahon H; Naidich DP; Goo JM
24, Suspected Cancer: Recognition and Referral. NICE Guideline NG. 2015;12.,Suspected Cancer: Recognition and Referral,NICE Guideline NG,2015,12,,,,,
25,"Young B, Vedhara K, Kendrick D. Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study. BMC Public Health. 2018;18:1276.",Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study,BMC Public Health,2018,18,,1276,,,Young B; Vedhara K; Kendrick D
26,"Clark ME, Bedford LE, Young B. Lung cancer CT screening: psychological responses in the presence and absence of pulmonary nodules. Lung Cancer. 2018;124.",Lung cancer CT screening: psychological responses in the presence and absence of pulmonary nodules,Lung Cancer,2018,124,,,,,Clark ME; Bedford LE; Young B
27, Scottish Cancer Registry. Scottish Cancer Registry. 2019;06.,Scottish Cancer Registry,Scottish Cancer Registry,2019,06,,,,,
28," World Health Organization. International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). World Health Organization. International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). 2015;None.","World Health Organization. International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)","World Health Organization. International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)",2015,,,,,,
29,"Swensen SJ, Jett JR, Hartman TE. CT screening for lung cancer: five-year prospective experience. Radiology. 2005;235.",CT screening for lung cancer: five-year prospective experience,Radiology,2005,235,,,,,Swensen SJ; Jett JR; Hartman TE
30,"Sharpe KH, Mcmahon AD, Raab GM. Association between socioeconomic factors and cancer risk: a population cohort study in Scotland (1991-2006). PLoS One. 2014;9:e89513.",Association between socioeconomic factors and cancer risk: a population cohort study in Scotland (1991-2006),PLoS One,2014,9,,e89513,,,Sharpe KH; Mcmahon AD; Raab GM
31,"Kinsinger LS, Anderson C, Kim J. Implementation of lung cancer screening in the Veterans Health Administration. JAMA Intern Med. 2017;177:399. doi:10.1183/13993003.00670-2020.",Implementation of lung cancer screening in the Veterans Health Administration,JAMA Intern Med,2017,177,,399,10.1183/13993003.00670-2020,,Kinsinger LS; Anderson C; Kim J
32,"Pinsky P, Miller A, Kramer B. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Epidemiol. 2007;165.","Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial",Am J Epidemiol,2007,165,,,,,Pinsky P; Miller A; Kramer B
33,"Tammemägi MC, Katki HA, Hocking WG. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368.",Selection criteria for lung-cancer screening,N Engl J Med,2013,368,,,,,Tammemägi MC; Katki HA; Hocking WG
34,"Schreuder A, Schaefer-Prokop CM, Scholten ET. Lung cancer risk to personalise annual and biennial follow-up computed tomography screening. Thorax. 2018;73.",Lung cancer risk to personalise annual and biennial follow-up computed tomography screening,Thorax,2018,73,,,,,Schreuder A; Schaefer-Prokop CM; Scholten ET
35,"Cooper GC, Harvie MN, French DP. Do negative screening test results cause false reassurance? A systematic review. Br J Health Psychol. 2017;22.",Do negative screening test results cause false reassurance? A systematic review,Br J Health Psychol,2017,22,,,,,Cooper GC; Harvie MN; French DP
36,"Edelsberg J, Weycker D, Atwood M. Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules. PLoS One. 2018;13:e0197826.",Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules,PLoS One,2018,13,,e0197826,,,Edelsberg J; Weycker D; Atwood M
37,"Zaenker P, Gray ES, Ziman MR. Autoantibody production in cancerthe humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev. 2016;15.",Autoantibody production in cancerthe humoral immune response toward autologous antigens in cancer patients,Autoimmun Rev,2016,15,,,,,Zaenker P; Gray ES; Ziman MR
38,"Massion PP, Healey GF, Peek LJ. Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer. J Thorac Oncol. 2017;12.",Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer,J Thorac Oncol,2017,12,,,,,Massion PP; Healey GF; Peek LJ
39,"Mckinney SM, Sieniek M, Godbole V. International evaluation of an AI system for breast cancer screening. Nature. 2020;577.",International evaluation of an AI system for breast cancer screening,Nature,2020,577,,,,,Mckinney SM; Sieniek M; Godbole V
40,"Balata H, Evison M, Sharman A. CT screening for lung cancer: are we ready to implement in Europe?. Lung Cancer. 2019;134. doi:10.1183/13993003.00670-2020.",CT screening for lung cancer: are we ready to implement in Europe?,Lung Cancer,2019,134,,,10.1183/13993003.00670-2020,,Balata H; Evison M; Sharman A
